63329-53-3Relevant articles and documents
Method for synthesizing N-o-carboxypnenyl-4-chloro-2-aminobenzoic acid serving as intermediate of lobenzarit medicine
-
Paragraph 0013; 0014, (2016/11/17)
A method for synthesizing N-o-carboxypnenyl-4-chloro-2-aminobenzoic acid serving as an intermediate of a lobenzarit medicines includes steps: (i) adding 400ml of diethyl ether, 0.079mol of 2-amino-4-chlorod-benzoic acid (2), 0.016-0.018mol of o-aminobenzoic acid (3), 0.19-0.21mol of ethylenediamine and 3.8g of nickel powder into a reaction vessel with a stirrer, a temperature gauge and a dropping funnel, controlling a stirring speed to be 180-210rpm, enabling a reflux reaction to last for 8-9h, leaching, dissolving a filter cake into 500ml of a salt solution, performing molecular sieve decoloration, adding an oxalic acid solution, keeping a pH value of the solution at 5-6, precipitating solids, filtering, washing with a potassium chloride solution, and recrystallizing in methylamine to obtain light yellow solid N-o-carboxypnenyl-4-chloro-2-aminobenzoic acid. The diethyl ether refers to absolute diethyl ether, and the salt solution refers to either a copper sulfate solution or a ferric nitrate solution.
Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents
Zhang, Bin,Chen, Kang,Wang, Ning,Gao, Chunmei,Sun, Qinsheng,Li, Lulu,Chen, Yuzong,Tan, Chunyan,Liu, Hongxia,Jiang, Yuyang
supporting information, p. 214 - 226 (2015/03/04)
A series of novel pyridyl acridone derivatives comprised of a pseudo-five-cyclic system to extend the π-conjugated acridone chromophore, were designed and synthesized as potent DNA binding antitumor compounds. Most synthesized compounds displayed good act
Potential antitumor agents. 38. 3-Substituted 5-carboxamido derivatives of amsacrine
Denny,Atwell,Baguley
, p. 1619 - 1625 (2007/10/02)
The synthesis and biological evaluation of a series of 3-substituted 5-carboxamido derivatives of amsacrine (m-AMSA) are described. This series was developed as the result of previous quantitative structure-activity relationship (QSAR) studies of the antitumor activity of 9-anilinoacridine derivatives. In agreement with these studies, this class of compounds, possessing a variety of small nonpolar groups at the 3-position, together with very hydrophilic carboxamido groups at the 5-position, have high in vivo activity against animal leukemia models.